Extended Spectrum Beta Lactamases Detection Using Two Phenotypic Methods Among Uropathogenic Escherichia Coli.

Chauhan S, Khanduri A, Mahawal B S.
Department of Microbiology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Patel Nagar, Dehradun. India.

Abstract: Background: Extended spectrum β-lactamases (ESBL) is an important mechanism of beta-lactam resistance among Gram negative bacteria. The ESBL detection method as described by Clinical Laboratory Standards Institute (CLSI) is used routinely. This method however is not able to detect ESBL in presence of AmpC which is another important mechanism of drug resistance among these bacteria. This study was thus undertaken to compare CLSI recommended method with Cefepime-clavulanic acid method.

Materials and Methods: A total of 216 non repetitive (Escherichia coli) E.coli isolates from urine samples were screened for resistance to Cefpodoxime and Cefotaxime. Those with screening test positive isolates were confirmed for ESBL production using the two phenotypic detection methods.

Results: Among total 216 E.coli isolates only 128 (59%) were potential ESBL producers. Of these 109 were positive by using CLSI recommended method while 112 by using Cefepime-clavulanic acid method. Conclusion: Use of Cefepime-clavulanic acid increases sensitivity for ESBL detection in presence of AmpC.

Keywords: AmpC β-lactamase, Cefepime, Ceftazidime, Extended Spectrum β-lactamase

I. Introduction

Extended spectrum β-lactamases (ESBL) are β-lactamases capable of conferring bacterial resistance to the Penicillins, first, second, and third-generation cephalosporins, and Aztreonam (but not the Cephemycins or Carbapenems) by hydrolysis of these antibiotics, and which are inhibited by β-lactam inhibitors such as clavulanic acid.[1] ESBLs belong to group 2be of Bush’s functional classification. AmpC β-lactamases belong to group 1 of Bush’s functional classification and are susceptible to advanced spectrum cephalosporins (i.e. cefepime and cefpirome).[2]

The ESBL confirmation method has been established by CLSI and is used worldwide.[3] This test however fails to detect ESBL in the presence of AmpC β-lactamases (AmpC).[4] Several methods have been described for detection of ESBL in presence of AmpC but these may not be routinely used.

The aim of the present study is to find the prevalence of ESBL producing E.coli causing urinary tract infections and to compare the two ESBL detection methods one given by CLSI using Ceftazidime-clavulanic acid and the other Cefepime-clavulanic acid.

II. Materials and Methods:

A total of 216 non repetitive E.coli isolates obtained from cultures of urine received between January 2012 to August 2012 were included in the study. Identification of these E. coli isolates was done using standard microbiological techniques. Antibiotic susceptibility testing was done according to CLSI recommended Kirby – Bauer disk diffusion method.[5]

Each of these E. coli isolates were screened for possible ESBL production by using 30µg of Cefotaxime and 10 µg of Cefpodoxime disk.

Every isolate that showed resistance to these screening agents was tested for ESBL detection by using (i) CLSI recommended method and (ii) cefepime-clavulanic acid method.

The interpretation of results was as follows:

1. A ≥ 5mm increase in the zone diameter of the Ceftazidime alone and in combination with Clavulanic acid was indicative of ESBL production as per CLSI.
2. A ≥ 5mm increase in the zone diameter of the Cefepime alone and in combination with Clavulanic acid was indicative of ESBL production even in presence of AmpC.[5,6,7]

E.coli ATCC 25922 was taken as negative control and K. pneumoniae ATCC 70603 served as positive control.

III. Results and Discussion:

A total of 1136 urine samples were received in the laboratory during the study period out of which 216 E.coli were isolated. These 216 E.coli isolates were then screened for ESBL production by CLSI recommended screening method using 30µg of Cefotaxime and 10 µg of Cefpodoxime. Though, any third generation...
**Extended Spectrum Beta Lactamases detection using two phenotypic methods among Uropathogeni…**

cephalosporin can be used, some workers have recommended Cefpodoxime disk as a good screening agent for ESBL detection in *E. coli*. The number of potential ESBL producers identified by CLSI recommended screening test were 128 (59%).

All screening test positive isolates were further tested for confirmation of ESBL production by CLSI recommended Phenotypic confirmatory test using Ceftazidime and Ceftazidime - Clavulanic acid and Disk Diffusion Method using Cefepime and Cefepime-Clavulanic acid.

Not all 128 screening test positive isolates were confirmed to be ESBL producers. Similarly other studies have also demonstrated that not all screen positive isolates were ESBL producers. Out of 128 screen test positive 109 (85.2%) isolates were positive by CLSI recommended method,112 (87.5%) were positive by Cefepime-Clavulanic acid method. Thus 3 isolates of *E.coli* would have been missed by using only CLSI recommended method. As shown in Table 1(A) and 1(B). This difference was found to be statistically significant (p value <0.05, Chi square test, Graph Pad).

The ESBL isolates showed maximum sensitivity to Imipenem and Tigecycline followed by Nitrofurantoin as shown in Figure:1.

In our study ESBL along with AmpC production accounted for 2.3% of *E.coli* isolates which were detected using Cefpime. Similar study from Chandigarh reported 2% of isolates having co-existence of Amp C and ESBLs. A study from Haldwani reported as high as 25% of ESBL and Amp C co-production.

In conclusion, the results of the study indicate that the current CLSI recommended method to confirm ESBL enzymes by conducting clavulane synergy tests with Ceftazidime may be insufficient for ESBL detection in clinical isolates of *E.coli* since this organism may produce multiple β-lactamases. In such situations, AmpC β-lactamase can interfere with clavulane synergy, Cefepime clavulane could be a more sensitive alternative for the detection of ESBL producing organisms. This is consistent with other studies.

**IV. Acknowledgement**

We are thankful to Mr. Durgesh Ramola, Senior Lab. Technician for his help in carrying out this study.

**References**


**Table 1(A) Comparison of CLSI Phenotypic confirmatory test using Ceftazidime/Ceftazidime-Clav with Cefpime/Cefpime-Clav:**

<table>
<thead>
<tr>
<th>Study</th>
<th>Total number</th>
<th>Positive by Ceftazidime/Ceftazidime-Clav</th>
<th>Positive by Cefpime/Cefpime-Clav</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>E.coli</em></td>
<td>128</td>
<td>109 (85.2%)</td>
<td>112 (87.5%)</td>
</tr>
</tbody>
</table>

www.iosrjournals.org 85 Page
Table 1(B): Comparison of CLSI Phenotypic confirmatory test using Ceftazidime/Ceftazidime-Clav with Cefepime/Cefepime-Clav:

<table>
<thead>
<tr>
<th>Study Isolate</th>
<th>Only Positive by Ceftazidime/Ceftazidime-Clav</th>
<th>Only Positive by Cefepime/Cefepime-Clav</th>
<th>Positive by Both</th>
<th>Negative by Both</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>E.coli</td>
<td>00</td>
<td>03</td>
<td>109</td>
<td>16</td>
<td>128</td>
</tr>
</tbody>
</table>

Figure 1: Sensitivity pattern of ESBL isolates.

![Sensitivity pattern of ESBL isolates](image-url)